Gastrointestinal Stromal Tumor Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Novartis, Pfizer, Bayer, DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics

DelveInsight's "Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Gastrointestinal Stromal Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastrointestinal Stromal Tumor Market Forecast
https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Gastrointestinal Stromal Tumor Market Report:
• The Gastrointestinal Stromal Tumor market size was valued approximately USD 454 in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, 15,140 GIST event cases are anticipated to occur overall in 2022. The US had the greatest incident rate of GIST cases in 2022 (6,528 instances), and this rate is predicted to climb sharply in the near future due to improvements in diagnostic tests and genetic testing.
• Based on mutation, the total incidence cases of GIST are divided into KIT mutation, PDGFRA mutation, BRAF mutation, and others. According to the evaluation, there will be 11,961 incident cases of KIT mutation, 1,629 incident cases of PDGFRA mutation, 137 incident cases of BRAF mutation, and 1,413 incident cases of other mutation in the 7MM in 2022
• There were 3,967 incident cases in the localised stage, 979 in the regional stage, 1,306 in the remote stage, and 276 in the unknown stage in the US in 2022, it was discovered
• Germany had the biggest incident population of GIST among the European nations in 2022, with 1,787 cases, followed by Italy with 1,162 instances. Spain, however, had the lowest occurrence rate (920 cases)
• Key Gastrointestinal Stromal Tumor Companies: Novartis, Pfizer, Bayer, DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., and others
• Key Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, AMG 706, Imatinib Mesylate, DCC-2618, Famitinib capsules, masitinib, Nilotinib, sunitinib malate, Regorafenib (Stivarga, BAY73-4506)
• The Gastrointestinal Stromal Tumor epidemiology based on gender analyzed that a higher percentage of incident cases was observed in males, than females, in all the 7MM countries
• The Gastrointestinal Stromal Tumor market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastrointestinal Stromal Tumor pipeline products will significantly revolutionize the Gastrointestinal Stromal Tumor market dynamics.

Gastrointestinal Stromal Tumor Overview
Gastrointestinal stromal tumour (GIST) is an uncommon kind of cancer that affects the digestive tract or adjacent structures in the abdomen, according to GIST Support International. Interstitial cells of Cajal (ICCs) or less differentiated stem cells or precursor cells that can grow into ICCs are the sources of this sarcoma.

Get a Free sample for the Gastrointestinal Stromal Tumor Market Report
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastrointestinal Stromal Tumor Epidemiology Segmentation:
The Gastrointestinal Stromal Tumor market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Gastrointestinal Stromal Tumor
• Prevalent Cases of Gastrointestinal Stromal Tumor by severity
• Gender-specific Prevalence of Gastrointestinal Stromal Tumor
• Diagnosed Cases of Episodic and Chronic Gastrointestinal Stromal Tumor

Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Epidemiology Forecast
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastrointestinal Stromal Tumor market or expected to get launched during the study period. The analysis covers Gastrointestinal Stromal Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastrointestinal Stromal Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastrointestinal Stromal Tumor Therapies and Key Companies
• TAS-116: Taiho Pharmaceutical
• Bezuclastinib: Cogent Biosciences, Inc./ Plexxikon
• Iclusig: Ariad Pharmaceuticals
• Cabozantinib: Exelixis
• THE-630: Theseus Pharmaceutical
• AMG 706: Amgen
• Imatinib Mesylate: Amneal Pharmaceuticals, LLC
• DCC-2618: Zai Lab (Shanghai) Co., Ltd.
• Famitinib capsules: Jiangsu HengRui Medicine Co., Ltd.
• masitinib: AB Science
• Nilotinib: Novartis
• sunitinib malate: Pfizer
• Regorafenib (Stivarga, BAY73-4506): Bayer

Discover more about therapies set to grab major Gastrointestinal Stromal Tumor market share @ Gastrointestinal Stromal Tumor Treatment Market
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Market Drivers
• Rich emerging Gastrointestinal Stromal Tumor pipeline
Increasing Gastrointestinal Stromal Tumor incidence
• Understanding of pathophysiology
• Increased awareness of Gastrointestinal Stromal Tumor
• Identification of solid tumor's treatment with NTRK gene fusions

Gastrointestinal Stromal Tumor Market Barriers
• Resistance against pharmacological therapies
• Clinical challenges in the management of disease
• High economic burden
• Side effects and adverse events after treatment

Scope of the Gastrointestinal Stromal Tumor Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastrointestinal Stromal Tumor Companies: Novartis, Pfizer, Bayer, DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., and others
• Key Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, AMG 706, Imatinib Mesylate, DCC-2618, Famitinib capsules, masitinib, Nilotinib, sunitinib malate, Regorafenib (Stivarga, BAY73-4506), and others
• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gastrointestinal Stromal Tumor Unmet Needs, KOL's views, Analyst's views, Gastrointestinal Stromal Tumor Market Access and Reimbursement

To know more about Gastrointestinal Stromal Tumor companies working in the treatment market, visit @ Gastrointestinal Stromal Tumor Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Gastrointestinal Stromal Tumor Market Report Introduction
2. Executive Summary for Gastrointestinal Stromal Tumor
3. SWOT analysis of Gastrointestinal Stromal Tumor
4. Gastrointestinal Stromal Tumor Patient Share (%) Overview at a Glance
5. Gastrointestinal Stromal Tumor Market Overview at a Glance
6. Gastrointestinal Stromal Tumor Disease Background and Overview
7. Gastrointestinal Stromal Tumor Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastrointestinal Stromal Tumor
9. Gastrointestinal Stromal Tumor Current Treatment and Medical Practices
10. Gastrointestinal Stromal Tumor Unmet Needs
11. Gastrointestinal Stromal Tumor Emerging Therapies
12. Gastrointestinal Stromal Tumor Market Outlook
13. Country-Wise Gastrointestinal Stromal Tumor Market Analysis (2019-2032)
14. Gastrointestinal Stromal Tumor Market Access and Reimbursement of Therapies
15. Gastrointestinal Stromal Tumor Market Drivers
16. Gastrointestinal Stromal Tumor Market Barriers
17. Gastrointestinal Stromal Tumor Appendix
18. Gastrointestinal Stromal Tumor Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Gastrointestinal Stromal Tumor Pipeline
https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Gastrointestinal Stromal Tumor Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Gastrointestinal Stromal Tumor market. A detailed picture of the Gastrointestinal Stromal Tumor pipeline landscape is provided, which includes the disease overview and Gastrointestinal Stromal Tumor treatment guidelines.
Gastrointestinal Stromal Tumor Epidemiology
https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastrointestinal Stromal Tumor Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Gastrointestinal Stromal Tumor epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.